Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-01-22
2008-01-22
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500, C435S006120, C435S091100, C435S325000, C435S375000
Reexamination Certificate
active
11588674
ABSTRACT:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan, Jr. et al.
patent: 4981957 (1991-01-01), Lebleu et al.
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5118800 (1992-06-01), Smith et al.
patent: 5138045 (1992-08-01), Cook et al.
patent: 5212295 (1993-05-01), Cook
patent: 5218105 (1993-06-01), Cook et al.
patent: 5223168 (1993-06-01), Holt
patent: 5319080 (1994-06-01), Leumann
patent: 5359044 (1994-10-01), Cook et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5386023 (1995-01-01), Sanghvi et al.
patent: 5393878 (1995-02-01), Leumann
patent: 5446137 (1995-08-01), Maag et al.
patent: 5457191 (1995-10-01), Cook et al.
patent: 5459255 (1995-10-01), Cook et al.
patent: 5466786 (1995-11-01), Buhr et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5506351 (1996-04-01), McGee
patent: 5514785 (1996-05-01), Van Ness et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5521302 (1996-05-01), Cook
patent: 5539082 (1996-07-01), Nielsen et al.
patent: 5541307 (1996-07-01), Cook et al.
patent: 5554746 (1996-09-01), Ravikumar et al.
patent: 5567811 (1996-10-01), Misiura et al.
patent: 5571902 (1996-11-01), Ravikumar et al.
patent: 5576427 (1996-11-01), Cook et al.
patent: 5578718 (1996-11-01), Cook et al.
patent: 5587361 (1996-12-01), Cook et al.
patent: 5587469 (1996-12-01), Cook et al.
patent: 5587470 (1996-12-01), Cook et al.
patent: 5591722 (1997-01-01), Montgomery et al.
patent: 5597909 (1997-01-01), Urdea et al.
patent: 5599797 (1997-02-01), Cook et al.
patent: 5602240 (1997-02-01), De Mesmaeker et al.
patent: 5608046 (1997-03-01), Cook et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5610300 (1997-03-01), Altmann et al.
patent: 5627053 (1997-05-01), Usman et al.
patent: 5639873 (1997-06-01), Barascut et al.
patent: 5646265 (1997-07-01), McGee
patent: 5658873 (1997-08-01), Bertsch-Frank et al.
patent: 5670633 (1997-09-01), Cook et al.
patent: 5686288 (1997-11-01), MacDonald et al.
patent: 5700920 (1997-12-01), Altmann et al.
patent: 5735814 (1998-04-01), Elsberry et al.
patent: 5814014 (1998-09-01), Elsberry et al.
patent: 5859221 (1999-01-01), Cook et al.
patent: 6042579 (2000-03-01), Elsberry et al.
patent: 6093180 (2000-07-01), Elsberry
patent: 6127533 (2000-10-01), Cook et al.
patent: 6166197 (2000-12-01), Cook et al.
patent: 6172209 (2001-01-01), Manoharan et al.
patent: 6262241 (2001-07-01), Cook et al.
patent: 6271358 (2001-08-01), Manoharan et al.
patent: 6551290 (2003-04-01), Elsberry et al.
patent: 6594880 (2003-07-01), Elsberry
patent: 6945969 (2005-09-01), Morris et al.
patent: 7189222 (2007-03-01), Elsberry
patent: 2001/0027309 (2001-10-01), Elsberry
patent: 2001/0027599 (2001-10-01), Elsberry
patent: 2003/0109476 (2003-06-01), Kmiec et al.
patent: 101 00 586 (2002-04-01), None
patent: WO 93/07883 (1993-04-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 99/53050 (1999-10-01), None
patent: WO 99/61631 (1999-12-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 2004/065601 (2004-08-01), None
Agrawal et al., “Antisense therapeutics: is it as simple as complementary base recognition?”Mol. Med. Today6:72-81 (2000).
Beaucage et al., “Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach”Tetrahedron48:2223-2311 (1992).
Boado et al., “Antisense-Mediated Down-Regulation of the Human Huntingtin Gene”J. Pharmacol. Exp. Ther.295:239-243 (2000).
Braasch et al., “Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA”Chem. Biol.8:1-7 (2001).
Braasch et al., “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression”Biochemistry41:4503-4510 (2002).
Branch, “A good antisense molecule is hard to find”Trends Biochem. Sci.23:45-50 (1998).
Cook, “Medicinal chemistry of antisense oligonucleotides—future opportunities”Anticancer Drug Des.6:585-607 (1991).
Crooke et al., “Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in mice”J. Pharmacol. Exp. Ther.277:923-937 (1996).
Delgado et al., “The Uses and Properties of PEG-Linked Proteins”Crit. Rev. Ther. Drug Carrier Syst.9;249-304 (1992).
Elbashir et al., “Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melanogasterembryo lysate”EMBO J.20:6877-6888 (2001).
GenBank Accession No. NM—002111, “Homo sapienshuntingtin (Huntington disease) (HD), mRNA” (Oct. 1, 2006).
GenBank Accession No. NM—010414, “Mus musculusHuntington disease gene homolog (Hdh), mRNA” (Oct. 23, 2006).
GenBank Accession No. U18650, “Rattus norvegicusHuntington gene product mRNA, complete cds” (Mar. 1, 1996).
Gewirtz et al., “Facilitating oligonucleotide delivery: Helping antisense deliver on its promise”Proc. Natl. Acad. Sci. USA93:3161-3163 (1996).
Guzaev et al., “A Conformationally Preorganized Universal Solid Support for Efficient Oligonucleotide Synthesis”J. Am. Chem. Soc.125:2380-2381 (2003).
Hamm et al., “Incorporation of 2′-Deoxy-2′-mercaptocytidine into Oligonucleotides via Phosphoramidite Chemistry”J. Org. Chem.62:3415-3420 (1997).
Hasholt et al., “Antisense downregulation of mutant huntingtin in a cell model”J. Gene Med.5:528-538 (2003).
Kabanov et al., “A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells”FEBS Lett.259:327-330 (1990).
Koshkin et al., “LNA (Locked Nucleic Acids): Synthesis of the Adenine, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil Bicyclonucleoside Monomers, Oligomerisation, and Unprecedented Nucleic Acid Recognition”Tetrahedron54:3607-3630 (1998).
Letsinger et al., “Cholesteryl-conjugated oligonucleotides: Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture”Proc. Natl. Acad. Sci. USA86:6553-6556 (1989).
Li et al., “Folate-Mediated Targeting of Antisense Oligodeoxynucleotides to Ovarian Cancer Cells”Pharm. Res.15:1540-1545 (1998).
Manoharan, “Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery, and Mechanism of Action”Antisense Nucleic Acid Drug Dev.12:103-128 (2002).
Manoharan et al., “Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides”Ann. NY Acad. Sci.660:306-309 (1992).
Manoharan et al., “Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications”Bioorg. Med. Chem. Lett.3(12):2765-2770 (1993).
Manoharan et al., “Cholic Acid-Oligonucleotide Conjugates for Antisense Applications”Bioorg. Med. Chem. Lett.4(8):1053-1060 (1994).
Manoharan et al., “Oligonucleotide Conjugates Alteration of the Pharmacokinetic Properties of Antisense Agents”Nucleosides&Nucleotides14:969-973 (1995).
Manoharan et al., “Lipidic Nucleic Acids”Tetrahedron36:3651-3654 (1995).
Martin, “A New Access to 2′-O-Alkylated Ribonucleosides and Properties of 2′-O-Alkylated Oligoribonucleotides”Helv. Chem. Acta78:486-504 (1995).
Martin et al, “Huntington's Disease. Pathogenesis and
Bramlage Birgit
Bumcrot David
Hadwiger Philipp
Roehl Ingo
Sah Dinah Wen-Yee
Alnylam Pharmaceuticals, Inc.
Fish & Richardson P.C.
Gibbs Terra Cotta
LandOfFree
Compositions and methods for inhibiting expression of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting expression of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting expression of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3930861